Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00664859 · ClinicalTrials.gov registry record · Phase 2

12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia

A Phase 2 study, sponsored by Veloxis Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
140
Enrollment target

NCT00664859 is a Phase 2 study that has completed, run by Veloxis Pharmaceuticals. The registered enrollment target is 140 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00664859, a Phase 2 study, has completed, sponsored by Veloxis Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
140 participants
Enrollment target

Study Summary

The current study is designed to test the long-term (12-month) safety and efficacy of LCP-AtorFen, a combination of atorvastatin and fenofibrate, in patients with dyslipidemia

Interventions

  • DRUG LCP-AtorFen

Trial Details

FieldValue
Enrollment Target 140 participants
Start Date 2007-10
Est. Completion 2009-02
Phase Phase 2

Sponsor

Veloxis Pharmaceuticals

15 total trials

What the Registry Record Tells You About NCT00664859

The ClinicalTrials.gov registry entry for NCT00664859 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Veloxis Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which LCP-AtorFen is the first listed.

NCT00664859 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00664859 about?

NCT00664859 is a clinical study titled "12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia". The current study is designed to test the long-term (12-month) safety and efficacy of LCP-AtorFen, a combination of atorvastatin and fenofibrate, in patients with dyslipidemia

What is the current status of trial NCT00664859?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2007-10. Estimated completion is 2009-02.

What interventions are being tested in trial NCT00664859?

The interventions under investigation include: LCP-AtorFen (DRUG).

Who is sponsoring clinical trial NCT00664859?

This trial is sponsored by Veloxis Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.